Yale Cancer Center | Strategic Alliance Partners

In a new study by Yale Cancer Center, researchers show stem-like T cells within certain lymph nodes could be natural cancer fighters.

Lakshmanan Krishnamurti, MD, has been named Chief of Pediatric Hematology, Oncology, and Bone Marrow Transplant at Yale New Haven Children’s Hospital and Leader of the Smilow Cancer Hospital Pediatric Hematology/Oncology Program.

A new study led by Yale Cancer Center scientists revealed the combination of ATR and PARP inhibitor therapies can effectively target the enzyme isocitrate dehydrogenase-I/2 (IDH-1/2) in mutant cancer cells.

Barbara Burtness, MD, has been appointed Interim Associate Director for Diversity, Equity, and Inclusion at Yale Cancer Center.

Researchers show the nucleoside transporter ENT2 may offer an unexpected path to circumventing the blood-brain barrier and enabling targeted treatment of brain tumors with a cell-penetrating anti-DNA autoantibody.

A revolutionary new urine screening test that utilizes a novel Keratin 17 cancer biomarker can detect the presence of new bladder cancer in patients with hematuria, or blood in the urine.

Yale Cancer Center and Smilow Cancer Hospital scientists and clinicians are presenting research studies at the 2021 Annual Virtual Meeting of the American Society of Clinical Oncology June 4-8.

In a new study led by Yale Cancer Center, researchers report many survivors of childhood cancers receive systemic therapies associated with cognitive effects and chronic health conditions that may impact long-term cognitive outcomes with downstream effects on education, employment, and income.

Anne Chiang, MD, PhD, has been appointed an Executive Officer of the Southwest Oncology Group Cancer Research Network.

Jill Lacy, MD, Professor of Medicine at Yale Cancer Center, was named a Fellow of the American Society of Clinical Oncology.

Sarah B. Goldberg, MD, MPH, discusses the toxicity profile associated with amivantamab in metastatic non–small cell lung cancer that harbors EGFR exon 20 insertion mutations.

Maryam Lustberg, MD, MPH, has been appointed Director of The Breast Center at Smilow Cancer Hospital and Chief of Breast Medical Oncology at Yale Cancer Center.

Edward Kaftan, PhD, has been appointed Assistant Cancer Center Director for Translational Science at Yale Cancer Center.

Enfortumab vedotin significantly prolonged survival as compared with standard chemotherapy in patients with locally advanced or metastatic urothelial carcinoma or bladder cancer, who had previously received platinum-based treatment and a PD-1–PD-L1 inhibitor.

Anne Chiang, MD, PhD, has been named Deputy Chief Medical Officer and Chief Integration Officer at Smilow Cancer Hospital.

January 25, 2021 - Rachel Adams Greenup, MD, MPH, FACS, has been appointed as Associate Professor of Surgery and Section Chief of Breast Surgery for the Department of Surgery at Yale School of Medicine.

In today’s episode, we had the pleasure of speaking with the faculty of a recent Institutional Perspectives in Cancer webinar on prostate cancer hosted by Yale Cancer Center.

Mario Sznol, MD, Yale Cancer Center, discusses the multidisciplinary management of toxicities associated with immunotherapy in patients with melanoma.

Mario Sznol, MD, discusses toxicities associated with immunotherapy in patients with melanoma.

Roy S. Herbst, MD, PhD, discusses the approval of adjuvant osimertinib in EGFR-positive non–small cell lung cancer.

Daniel P. Petrylak, MD, highlights the use of abiraterone acetate, enzalutamide, and apalutamide and how these agents can lead to improvements in overall survival and progression-free survival in patients with hormone-sensitive prostate cancer.

Michael E. Hurwitz, MD, PhD, highlights the role of second-generation androgen blockers in nonmetastatic castration-resistant prostate cancer, how these agents compare, and active areas of investigation.

Lajos Pusztai, MD, DPhil, discusses the promise of circulating tumor DNA assays in breast cancer.

Mario Sznol, MD, discusses the challenges of managing immune-related toxicities in melanoma.

December 10, 2020 — Despite gene expression tests helping health care professionals make optimal treatment decisions, testing varies by region for men with prostate cancer and could be related to socioeconomic status and patterns of prostate cancer care.

Daniel P. Petrylak, MD, discusses the role of docetaxel based on the results of the ENZAMET trial in metastatic hormone-sensitive prostate cancer.

Daniel P. Petrylak, MD, discusses future research in prostate cancer.

Daniel P. Petrylak, MD, discusses the ever-changing prostate cancer armamentarium, as well as the role of biomarkers and new diagnostic methods in the space.

Daniel P. Petrylak, MD, discusses the utility of tissue biopsy versus liquid biopsy in prostate cancer.